Gustave Roussy, Cancer Campus, Grand Paris
gustaveroussy.frLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
239
Active
69
Phase 3
62
Total enrollment
110,538
Pipeline matrix
Showing 40 of 103 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Nivolumab | — | — | 8 | ||||
| Cabozantinib | — | — | — | — | 2 | ||
| Ipilimumab | — | — | — | 7 | |||
| Olaparib | — | — | — | — | 5 | ||
| Cisplatin | — | — | — | 9 | |||
| Pembrolizumab | — | — | — | 6 | |||
| Carboplatin | — | — | — | 5 | |||
| Everolimus | — | — | — | 5 | |||
| Irinotecan | — | — | — | — | 4 | ||
| Lenvatinib | — | — | — | — | 2 | ||
| etoposide | — | — | — | — | 5 | ||
| Doxorubicin | — | — | — | — | 3 | ||
| Thiotepa | — | — | — | — | 3 | ||
| Vindesine | — | — | — | — | — | 2 | |
| Ifosfamide | — | — | — | — | — | 2 | |
| Melphalan | — | — | — | — | 2 | ||
| Venetoclax | — | — | — | — | — | 1 | |
| Azacitidine | — | — | — | — | — | 1 | |
| Experimental | — | — | — | — | — | 1 | |
| rhTSH stimulation | — | — | — | — | — | 1 | |
| I131 | — | — | — | — | — | 1 | |
| Thromboprophylaxis | — | — | — | — | — | 1 | |
| Adjuvant chemotherapy with Capecitabine-Temozolomide | — | — | — | — | — | 1 | |
| CBD oil | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Dacarbazine | — | — | — | — | — | 1 | |
| Busulfan | — | — | — | — | — | 1 | |
| Dinutuximab Beta | — | — | — | — | — | 1 | |
| Temozolomide 100 MG | — | — | — | — | — | 1 | |
| Cyclophosphamid | — | — | — | — | — | 1 | |
| ONC201 | — | — | — | — | — | 1 | |
| SoC-based immunotherapy | — | — | — | — | — | 1 | |
| Tislelizumab | — | — | — | — | — | 1 | |
| Pembrolizumab 200 mg Q6W | — | — | — | — | — | 1 | |
| Pemetrexed 500 mg/m^2 Q3W | — | — | — | — | — | 1 | |
| Pembrolizumab 200 mg Q3W or 400 mg Q6W | — | — | — | — | — | 1 | |
| HPV vaccine | — | — | — | — | — | 1 | |
| Acetylsalicylic acid | — | — | — | — | — | 1 | |
| Atorvastatin | — | — | — | — | — | 1 | |
| axitinib | — | — | — | — | 2 |
63 more active programs hidden
Next readouts
- 2022-04-01
- 2022-11-04
- 2025-11
- 2025-12-17
- 2026-04
- 2026-06
- 2026-09
- 2026-11
- 2026-11
- 2027-01
Top conditions
- Breast Cancer14
- Cancer10
- Lung Cancer6
- Prostate Cancer6
- Colorectal Cancer5
- Metastatic Cancer5
- Non Small Cell Lung Cancer5
- Thyroid Cancer4
Frequently asked questions about Gustave Roussy, Cancer Campus, Grand Paris
- How many clinical trials does Gustave Roussy, Cancer Campus, Grand Paris have on ClinicalTrials.gov?
- Gustave Roussy, Cancer Campus, Grand Paris is listed as the lead sponsor on 239 clinical trials in ClinicalTrials.gov, 69 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Gustave Roussy, Cancer Campus, Grand Paris's trials are in Phase 3?
- 62 of Gustave Roussy, Cancer Campus, Grand Paris's trials are in Phase 3, spread across 103 active drug programs.
- What therapeutic areas does Gustave Roussy, Cancer Campus, Grand Paris focus on?
- Gustave Roussy, Cancer Campus, Grand Paris's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer.
- When are Gustave Roussy, Cancer Campus, Grand Paris's next clinical trial readouts?
- Gustave Roussy, Cancer Campus, Grand Paris has 10 upcoming primary-completion readouts tracked here; the soonest is “Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?”, expected around 2022-04-01.